Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN® vaccine against COVID-19
Interim guidance
15 March 2022
| COVID-19: Vaccines
Overview
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were
developed on the basis of advice issued by the Strategic Advisory Group
of Experts on Immunization (SAGE) and the evidence summary included in
the background document and annexes referenced below.
This document has been updated: version 15 March 2022.
For translations of this document in other languages, click here.
WHO Team
Agenda, Policy & Strategy (APS),
Immunization, Vaccines and Biologicals (IVB),
Strategic Advisory Group of Experts on Immunization,
WHO Headquarters (HQ)
Number of pages
9
Reference numbers
WHO Reference Number: WHO/2019-nCoV/vaccines/SAGE_recommendation/BBV152/2021.1